Getting On – And Staying In – the EMA’s PRIME Scheme
Executive Summary
Companies won’t necessarily lose their place on the European Medicines Agency’s priority medicines scheme if a competing product gets to market first. And they shouldn’t be put off by the fact that competing products are already on the scheme.
You may also be interested in...
EMA’s PRIME A Year On: Hits And Misses When It Comes To Applications
Three out of four applications have been denied entry to the European Medicines Agency’s priority medicines (PRIME) scheme for getting drugs for unmet medical needs to patients faster. Robert Hemmings, who chairs the EMA’s scientific advice working party, explains why.
Accelerated Assessment Decision ‘Imminent’ For Two Products In EMA’s PRIME Scheme
The sponsors of two products in the European Medicines Agency’s popular PRIME scheme for speeding patient access to drugs for unmet medical needs appear to be close to filing their applications for marketing authorization. Five more products were accepted on the scheme this week.
Blood Disorders Overtake Cancer On EMA’s PRIME Scheme
uniQure has become the third company to get accepted on the European Medicines Agency’s PRIME (priority medicines) scheme for a gene therapy for hemophilia, making hematology-hemostaseology the most common therapeutic areas for products on the scheme.